Efficacy Testing in Oncology

Most of drug candidates have to demonstrate their efficacies in animals before entering human clinical trials. Animal models for human diseases can provide not only how good treatment results of the drug candidates are but also how the body system processes the drug candidates. Many critical questions can be answered based on the animal in vivo testing, such as effective dosage, route of administration, treatment schedule, target validation, PK/PD, and translational biomarker analysis.

Cephrim Biosciences offer pharmacological screening services to help identify lead compounds for future development and preclinical assessment of toxicology and safety.
Selected lead compounds can be analyzed in more sophisticated animal disease models to establish in vivo proof-of-principle. Disease models in the areas of cancer, inflammatory diseases, nephrology, neurology, metabolism/diabetes, and reproductive are currently available for efficacy testing and the analysis of biomarkers. If requested, further optimization of dosing, scheduling, and formulation can also be performed.
Efficacy testing of single agents or compound combinations in rodent disease models:

  • Oncology
  • Immunology/Inflammation
  • Nephrology
  • Neurology
  • Metabolism/Diabetes
  • Reproductive